We expect to be the first with a living cell treatment approved for this application, with site-specific regeneration,” said MacKay.
http://www.masshightech.com/stories...outh-tissue-research-gain-tech-attention.html
The company has already completed CelTx Phase 3 trials, and is finalizing data for approval submission to the U.S. Food and Drug Administration by the year’s end, he said.
Terrence Griffin, associate professor of the Tufts University School of Dental Medicine in Boston, has his own unique treatment. This involves applying platelet-rich blood plasma to the receding gums, which causes clotting that promotes new blood vessels, collagen synthesis, and the growth of new bone over the roots, he said.
griffin study was done on humans over a period of 4 years i think or 5, anyway achived better results than the more traditional method which isnt 100% effective.